ACRX - アセルRX・ファ―マシュ―ティカルズ （AcelRx Pharmaceuticals Inc.） アセルRX・ファ―マシュ―ティカルズACRXのチャート
ACRXの企業情報
| symbol | ACRx |
|---|---|
| 会社名 | AcelRx Pharmaceuticals Inc （アセルRX・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 AcelRx Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04 Zalviso which utilize sublingual sufentanil delivered through a non-invasive route of administration and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation anxiety reduction and pain relief for patients undergoing painful procedures in a physician''s office. It also includes ARX-02 which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer. アセルRX・ファ―マシュ―ティカルズは米国の医薬品会社。急性疼痛や突出痛用の治療薬の開発と商業化に重点を置く。候補薬には入院患者向け急性痛自己治療システム｢Zalviso｣、および救急処置室や救急病院用の中度・重度疼痛治療のスフェンタニルナノ粒子錠剤がある。本社はカリフォルニア州。 AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development and commercialization of therapies for the treatment of acute pain. |
| 本社所在地 | 351 Galveston Drive Redwood City CA 94063 USA |
| 代表者氏名 | Adrian Adams エイドリアンアダムス |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-216-3500 |
| 設立年月日 | 38534 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 41人 |
| url | www.acelrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.00100 |
| 終値（lastsale） | 2.99 |
| 時価総額（marketcap） | 181193742.86 |
| 時価総額 | 時価総額（百万ドル） 160.58980 |
| 売上高 | 売上高（百万ドル） 3.38800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 215.42480 |
| 当期純利益 | 当期純利益（百万ドル） -10.92800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AcelRx Pharmaceuticals Inc revenues decreased 80% to $1.2M. Net loss decreased 23% to $22.1M. Revenues reflect Collaboration agreement revenue decrease of 88% to $625K Contract and other decrease of 2% to $536K. Lower net loss reflects Research and development - Balancing val decrease of 45% to $6M (expense) General and Administrative - Balancing v decrease of 6% to $6.8M (expense). |
ACRXのテクニカル分析
ACRXのニュース
After Years Of Development, AcelRx's Dsuvia Has Finally Generated Revenue 2019-05-16
Last week, on Wednesday, May 8, AcelRx (NASDAQ: ACRX ) reported its financial results from the first quarter of 2019 . Though there has not been a huge amount of news to report since the company's last business update in March , it nevertheless appears that AcelRx is moving steadily along w…
Week 18 Breakout Forecast: Short-Term Picks To Give You An Edge 2019-04-28
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 102 weeks of public selections as part of this ongoing live forward-testing. In…
AcelRx to announce first quarter 2019 results and provide an update on the company's business on Wednesday, May 8th, 2019 2019-04-25 PR Newswire
REDWOOD CITY, Calif. , April 25, 2019 /PRNewswire/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 8th, 2019 . AcelRx management will host a …
Study links opioid prescriptions to marketing spend 2019-01-18
A study just published in JAMA Open Network conducted by researchers at Brown University found a strong link between the amount spent on marketing by opioid manufacturers and the number of prescriptions written by doctors, leading to a rise in opioid overdose deaths. More news on: Endo…